EM1712E "Well Differentiated Neuroendocrine Tumors past, present and future

The purpose of this presentation is to provide a summary and discussion of the current definition, epidemiology, pathophysiology, prognostic factors, new imaging modalities and level 1 evidence systemic therapies for patients with well differentiated pancreatic and non-pancreatic neuroendocrine tumors. A list of priorities for future clinical research is mentioned at the end of the presentation.

Download Protocol

Target Audience

UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

  • Understand the definition and epidemiology of well differentiated neuroendocrine tumors.
  • Describe the role of somatostatin, somatostatin receptors and serotonin in well differentiated neuroendocrine tumors.
  • Describe clinical and molecular prognostic factors in well differentiated neuroendocrine tumors.
  • Understand the role of 68Gallium Dodatate PET scan in the evaluation of patients with well differentiated neuroendocrine tumors.
  • Describe level 1 evidence systemic therapies for metastatic well differentiated neuroendocrine tumors.
  • Describe the role of telotristat for the treatment of carcinoid diarrhea.
Course summary
Available credit: 
  • 1.00 AMA
Course opens: 
12/13/2017
Course expires: 
01/12/2018
Cost:
$0.00
Rating: 
0

Photo: Yull Arriaga, M.D.Yull E. Arriaga, M.D.
Associate Professor
Division of Hematology / Oncology

Dr. Arriaga is focused on giving his patients better cancer treatments and improving their quality of life. He believes that a multidisciplinary approach is the best way to treat patients with cancer. He specializes in Genitourinary (GU) and Gastrointestinal (GI) Medical Oncology. He is vice-chair of the Data and Safety Monitoring Committee (DSMC) at the Simmons Cancer Center. He is the principal investigator of several clinical trials in genitourinary medical oncology.

Available Credit

  • 1.00 AMA

Accreditation Period

Course opens: 
12/13/2017
Course expires: 
01/12/2018

Price

Cost:
$0.00
Please login or create an account to take this course.

Required Hardware/software

Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox and Google Chrome